Systemic Lupus Erythematosus (SLE).Care & specialists in Brazil

Lupus is not curable, but it is highly controllable. With hydroxychloroquine for every patient, targeted biologics such as belimumab and anifrolumab for moderate-to-severe disease, and tight steroid tapering, the majority of patients achieve low disease activity or remission and have a normal life expectancy. Lifelong therapy is the rule, similar to managing diabetes or hypertension.

5-year survival now exceeds 95 percent and 10-year survival is around 90 percent in high-income countries. Outcomes are better with early diagnosis, hydroxychloroquine adherence, and aggressive cardiovascular risk management. Lupus nephritis, neuropsychiatric involvement, and antiphospholipid syndrome are the strongest predictors of worse outcome.

The most common early features are persistent fatigue, joint pain in the hands and wrists, a sun-triggered rash across the cheeks, painless mouth ulcers, hair thinning, and Raynaud phenomenon. A positive antinuclear antibody on routine bloodwork in a young woman with any of these features should prompt rheumatology referral.

Diagnosis combines clinical features with serology. The 2019 EULAR/ACR criteria require an antinuclear antibody titer of at least 1:80 plus weighted criteria across seven clinical and three immunologic domains, totaling 10 points or more. Specific antibodies (anti-dsDNA, anti-Smith, anti-Ro, anti-La, antiphospholipid) and complement levels (C3, C4) refine the picture.

No. ANA is positive in around 99 percent of lupus patients but also in 10-15 percent of healthy adults and in many other autoimmune conditions. A positive ANA only matters when paired with compatible symptoms or other autoantibodies. Isolated low-titer ANA in a person with no symptoms does not need workup beyond reassurance.

Common triggers include ultraviolet light exposure, infections, surgical stress, pregnancy and the postpartum period, missed medications, sleep deprivation, smoking, certain drugs (sulfa antibiotics, hydralazine), and emotional stress. Identifying personal triggers through a symptom diary helps prevent flares.

The malar or butterfly rash is a raised red rash across the cheeks and bridge of the nose that spares the nasolabial folds. It is photo-sensitive, lasts days to weeks, heals without scarring, and appears in 30-60 percent of lupus patients. The discoid rash is different: disc-shaped, scaly, scarring, and most often on scalp, ears, and face.

Yes. Men make up around 10 percent of lupus cases during reproductive years and a higher share in older onset. Male-onset disease tends to be more severe with higher rates of renal involvement, cardiovascular events, and thrombosis. Diagnosis is often delayed because clinicians anchor on the female predominance.

There is a strong genetic component. Identical twin concordance is 24-58 percent and first-degree relative risk is 8-29 times baseline. More than 100 risk loci have been mapped including HLA-DR2/DR3 and complement gene variants. Most cases are still sporadic and environmental triggers shape who actually develops disease.

Yes, but planning matters. Aim for at least 6 months of quiescent disease before conception, continue hydroxychloroquine, switch off mycophenolate, methotrexate, and cyclophosphamide before pregnancy, start low-dose aspirin at 12 weeks, and co-manage with maternal-fetal medicine. Anti-Ro-positive mothers need fetal cardiac monitoring for congenital heart block.

For proliferative lupus nephritis (Class III or IV), induction is mycophenolate mofetil 2-3 g per day or low-dose intravenous cyclophosphamide on the Euro-Lupus schedule, paired with steroid taper. Voclosporin or belimumab can be added as triple therapy. Maintenance is mycophenolate or azathioprine for at least 3 years. The goal is complete renal response by 12 months.

Hydroxychloroquine reduces flares by about 50 percent, cuts thrombotic events, lowers all-cause mortality (HR around 0.6), and protects against organ damage accumulation. It is recommended for every lupus patient unless contraindicated. Annual eye screening after 5 years checks for rare retinal toxicity.

Rheumatoid arthritis is a small-joint erosive arthritis with positive rheumatoid factor and anti-CCP antibodies, morning stiffness over an hour, and joint deformity. Lupus arthritis is non-erosive, accompanied by ANA, anti-dsDNA, and anti-Smith antibodies, and presents with systemic features like rash, serositis, cytopenias, and nephritis that rheumatoid arthritis does not produce.

Yes. Neuropsychiatric lupus affects 20-40 percent of patients and includes cognitive dysfunction (lupus fog), headaches, mood disorders, seizures, psychosis, stroke, and peripheral neuropathy. Diagnosis combines clinical assessment, MRI, lumbar puncture if indicated, and exclusion of infection and metabolic causes.

You do not need to avoid the sun entirely, but daily broad-spectrum SPF 50 or higher sunscreen, sun-protective clothing, and avoidance of peak midday exposure are essential. Ultraviolet light triggers cutaneous and systemic flares in two-thirds of patients and damages keratinocyte DNA in a way that drives autoantigen exposure.

Yes. Belimumab improved overall lupus activity in the BLISS trials and renal response (from 32 to 43 percent complete response) in BLISS-LN. Anifrolumab achieved BICLA response in 47.8 percent versus 31.5 percent on placebo at week 52 in TULIP-2, with notable benefit for skin and joint disease. Both are added on top of standard therapy.

Anti-dsDNA antibody and complement levels (C3, C4) are the key activity markers — dsDNA rises and complement falls during flares, especially renal flares. Urinalysis with protein-to-creatinine ratio detects renal involvement early. Complete blood count and ESR or CRP complete the routine flare panel.

Yes. Around 20-30 percent of patients achieve sustained remission on minimal therapy after years of treatment, and many more reach low disease activity. Remission is defined by a low SLEDAI score, no clinical activity, and minimal or no glucocorticoids. Hydroxychloroquine is usually continued indefinitely even in remission.

Yes. African, Hispanic, Asian, and Indigenous populations have 2-4 times higher prevalence than white populations and develop disease at younger ages with more severe organ involvement and worse renal outcomes. Black women in the US have the highest national prevalence and a 3-fold higher rate of lupus nephritis.

Median time from first symptom to diagnosis is around 2 years, often longer in men and in patients without a classic malar rash. Early features such as fatigue and joint pain overlap with many other conditions, and serology takes time to evolve. Persistence with a rheumatologist when symptoms recur usually leads to an accurate diagnosis.

Diet does not cause or cure lupus, but a Mediterranean-style pattern, vitamin D repletion, and adequate calcium support cardiovascular and bone health that lupus and its treatment otherwise compromise. Avoid alfalfa sprouts (L-canavanine has triggered flares in case reports) and limit salt during steroid courses or active nephritis.

Cumulative steroid dose is the single most modifiable predictor of long-term organ damage in lupus — including avascular necrosis, osteoporosis, cataracts, diabetes, and infections. EULAR 2023 targets 5 mg per day of prednisone or less, and ideally off, with steroid-sparing immunosuppressants and biologics doing the long-term work.